Skip to content

US · CNSP · BIOTECHNOLOGY

CNS Pharmaceuticals, Inc. (CNSP) intrinsic value and stock valuation

$3.56as of 2026-11-21 · Mkt cap 3.1M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CNS Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values CNSP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CNSP’s statements →

CNS Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77027 cnspharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-15.85M
20172025
Free cash flow
-$-13.83M
20172025
Total equity
$4.52M-20.2% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-15.99M-$-14.9M-$-18.87M-$-14.93M-$-14.49M
Net income-$-15.85M-$-14.86M-$-18.85M-$-15.27M-$-14.5M
EPSd-$-36.02M-$-495.33M———
Operating cash flow-$-13.81M-$-17.11M-$-14.14M-$-10.56M-$-13.54M
Capital expenditure-$-20K-$0.00-$0.00-$0.00-$-10K
Free cash flow-$-13.83M-$-17.12M-$-14.14M-$-10.56M-$-13.54M
Total assets$8.62M$8.7M$1.7M$13.1M$8.76M
Total debt$330K$330K$300K$410K$390K
Net debt-$-6.87M-$-6.14M-$-250K-$-9.65M-$-4.62M
Total equity$4.52M$6.18M-$-4.43M$8.13M$6.62M
Cash and short-term investments$7.2M$6.46M$550K$10.1M$5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$10K$10K
Gross profit$0.00-$0.00-$0.00-$-10K-$-10K
Research and development expenses$9.77M$9.29M$14.1M$9.3M$9.81M
Selling, general and administrative expenses$6.21M$5.61M$4.77M$5.62M$4.67M
Other expenses-$0.00$0.00-$0.00$0.00$0.00
Operating expenses$16M$14.9M$18.9M$14.9M$14.5M
Cost and expenses$16M$14.9M$18.9M$14.9M$14.5M
Interest income$150K$60K$30K$0.00$0.00
Interest expense$20K$20K$10K$10K$10K
Depreciation and amortization$0.00$0.00$0.00$10K$10K
Ebitda-$-15.83M-$-14.84M-$-18.83M-$-15.26M-$-14.47M
Operating income-$-15.99M-$-14.9M-$-18.87M-$-14.93M-$-14.49M
Total other income/expenses, net$140K$40K$10K-$-340K-$-10K
Income before tax-$-15.85M-$-14.86M-$-18.85M-$-15.27M-$-14.5M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-15.85M-$-14.86M-$-18.85M-$-15.27M-$-14.5M
Weighted average shares outstanding$440K$30K$0.00$0.00$0.00
Weighted average diluted shares outstanding$440K$30K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$7.2M$6.46M$550K$10.1M$5M
Net receivables$0.00$880K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.1M$8.66M$1.59M$12.6M$7.48M
Property, plant and equipment, net$20K$10K$0.00$10K$20K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$520K$40K$110K$490K$1.28M
Total assets$8.62M$8.7M$1.7M$13.1M$8.76M
Accounts payable$3.77M$2.2M$5.83M$3.68M$1.52M
Short-term debt$330K$330K$300K$410K$390K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.1M$2.52M$6.13M$4.92M$2.14M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$4.1M$2.52M$6.13M$4.92M$2.14M
Common stock$0.00$0.00$10K$0.00$30K
Retained earnings-$-100.28M-$-84.42M-$-69.57M-$-50.72M-$-34.98M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$4.52M$6.18M-$-4.43M$8.13M$6.62M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$330K$330K$300K$410K$390K
Net debt-$-6.87M-$-6.14M-$-250K-$-9.65M-$-4.62M
Cash flow statement
20252024202320222021
Net income-$-15.85M-$-14.86M-$-18.85M-$-15.27M-$-14.5M
Depreciation and amortization$0.00$0.00$0.00$10K$10K
Stock-based compensation$190K$840K$1.01M$1.2M$1.72M
Change in working capital$1.85M-$-3.69M$3.7M$3.16M-$-780K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00-$-3.63M$1.32M$1.7M$1.04M
Net cash provided by operating activities-$-13.81M-$-17.11M-$-14.14M-$-10.56M-$-13.54M
Investments in property, plant and equipment-$-20K-$0.00-$0.00-$0.00-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20K-$0.00-$0.00-$0.00-$-10K
Common stock issued$14.1M$23.4M$2.32M$16M$4.65M
Common stock repurchased-$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.6M$23M$4.64M$15.6M$4.51M
Net change in cash$740K$5.91M-$-9.51M$5.05M-$-9.03M
Cash at end of period$7.2M$6.46M$550K$10.1M$5M
Operating cash flow-$-13.81M-$-17.11M-$-14.14M-$-10.56M-$-13.54M
Capital expenditure-$-20K-$0.00-$0.00-$0.00-$-10K
Free cash flow-$-13.83M-$-17.12M-$-14.14M-$-10.56M-$-13.54M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CNS Pharmaceuticals, Inc.

        CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

        CEO
        Rami Levin
        Employees
        8
        Beta
        1.02

        Explore

        Frequently asked questions

        What is the intrinsic value of CNS Pharmaceuticals, Inc. (CNSP)?

        InvestorsCraft does not currently publish an intrinsic value for CNSP. How the IC value is calculated.

        Is CNSP undervalued?

        InvestorsCraft does not publish an undervaluation signal for CNSP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.